Login / Signup

Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.

Dejan MicicIan RobinsonTanya KiddBrian TerreriBram P Raphael
Published in: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2024)
Teduglutide treatment was associated with reductions in liver chemistries by week 24, which is beneficial for patients with SBS-IF beyond improvements in parenteral nutrition and/or intravenous fluid dependence. Future studies should examine how long-term teduglutide might mitigate the risk of liver disease in patients with SBS-IF.
Keyphrases
  • high dose
  • current status
  • case report
  • low dose
  • combination therapy
  • clinical trial
  • placebo controlled
  • double blind